

### In the Claims

Please replace the previous version of the claims with the following:

1.-43. (Cancelled)

44. (Currently Amended) A pharmaceutical composition comprising:

a therapeutically effective amount of an antigen presenting dendritic cell comprising antigens from an autologous, ~~pulsed with an~~ inactivated, non-recombinant human immunodeficiency virus (HIV) isolated from blood tissue and obtained from a monocyte by plastic-adherence followed by culture with GM-CSF and IL-4 ; and

a pharmaceutically acceptable carrier;

wherein the inactivated human immunodeficiency virus is chemically inactivated by 2,2'-dithiopyridine, the composition expands *in vivo* expression of virus-specific CD8+ T-cells, and said virus-specific CD8+ T-cells kill HIV-infected cells, ~~and said inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.~~

45. – 51. (Cancelled)

52. (Currently Amended) The pharmaceutical composition of Claim ~~[[43]]~~ 44, further comprising an adjuvant ~~for optimizing the virus-specific CTL response.~~

53. (Previously Presented) The pharmaceutical composition of claim 52, wherein said adjuvant is a protease inhibitor.

54. (Previously Presented) The pharmaceutical composition of claim 53, wherein said protease inhibitor is indinavir.

55. (Previously Presented) The pharmaceutical composition of claim 54, wherein said composition comprises non-antiviral concentration of indinavir.

56. (Previously Presented) The pharmaceutical composition of claim 55, comprising a concentration of indinavir of 10 nM.